A Study of Mirikizumab (LY3074828) in Participants With Moderately to Severely Active Ulcerative Colitis

Summary

A study to investigate bowel urgency in adults with moderately to severely active ulcerative colitis (UC) treated with mirikizumab. The study will have 4 periods and will last for 36 weeks.

Timeline

Start

2023-05-17

Primary completion

2024-08-09

Completion

2026-04-27

Publications

• Danese S, Dignass A, Laharie D, Limdi JK, Kempinski R, Lewis JD, Younes Z, Cohen E, Alaka K, Eastman WJ, Tian T, Redondo I, Rubin DT, Dubinsky M. Mirikizumab is associated with rapid and sustained improvements in novel measures of bowel urgency in moderately-to-severely active ulcerative colitis: 28-week results from the LUCENT-URGE trial. J Crohns Colitis. 2026 May 8;20(5):jjag049. doi: 10.1093/ecco-jcc/jjag049.

Drugs

Indications